Sanofi
Signal active
Investment Firm
Overview
Sanofi offers research, development, manufacturing, and marketing of innovative therapeutic solutions. It covers areas such as diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health, and the new G enzyme.
Highlights
Founded
1973
Industry
Life Science
Employees
10001+
Investment
34
Lead Investment
19
Exits
13
Stages
Early Stage Venture, Private Equity, Late Stage Venture, Seed
Investor Type
N/A
Location
Paris, Ile-de-France, France, Europe
Contact Information
Social
Profile Resume
Sanofi, established in 1973 and headquartered in Europe., specializes in Early Stage Venture, Private Equity, Late Stage Venture, Seed investments across Biotechnology, Health Care, Pharmaceutical, Financial Services, Venture Capital, Impact Investing, Business Development, Financial Exchanges, Search Engine, Genetics. The organization boasts a portfolio of 34 investments, with an average round size of $93.6M and 13 successful exits. Their recent investments include Esperance Pharmaceuticals, Advantage Capital, Louisiana Funds, Warp Drive Bio, Third Rock Ventures. The highest investment round they participated in was $212.5B. Among their most notable exits are Esperance Pharmaceuticals and Advantage Capital. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Sanofi has made 34 investments. Their most recent investment was on Jun 26, 2024, when CTIBiotech raised $535.5K.
Sanofi has made 6 diversity investments. Their most recent diversity investment was on Jun 27, 2024, when Vigil Neuroscience raised $40.0M.
investments
34
Diversity investments
6
Lead investments
19
Number of exits
13
Investments
34
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Mar 21, 2024 | Mirador Therapeutics | Health Care | 400.0M |
| Jun 26, 2024 | Formation Bio | Biotechnology | 372.0M |
| Jun 26, 2024 | CTIBiotech | Biotechnology | 535.5K |
| Jun 27, 2024 | Vigil Neuroscience | Biotechnology | 40.0M |
Exits
13
Funding Timeline
Funding rounds
34
Investors
2
Funds
0
Funding Rounds
34
Sanofi has raised 34 rounds. Their latest funding was raised on Jun 27, 2024 from a Post-IPO Equity - Vigil Neuroscience round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Mar 21, 2024 | Series A - Mirador Therapeutics | - | 400.0M | - |
| Jun 26, 2024 | Series D - Formation Bio | - | 372.0M | - |
| Jun 26, 2024 | Grant - CTIBiotech | - | 535.5K | - |
| Jun 27, 2024 | Post-IPO Equity - Vigil Neuroscience | - | 40.0M | - |
Investors
2
Sanofi is funded by 2 investor(s). Blackstone Life Sciences and Evotec Kantor are the most recent investors.
| Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|
Evotec | Yes | Post-IPO Equity - Sanofi | 310.0M |
Blackstone Life Sciences | Yes | Post-IPO Equity - Sanofi | 329.0M |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
News
Sep 24, 2024
Bloomberg - Lenders Line Up Over €10 Billion for Sanofi Health Unit Buyout
News
Sep 23, 2024
sdbn.org - Is Sanofi making a move into obesity? French pharma invests $27M into Ventyx
News
Sep 23, 2024
sdbn.org - Sanofi scoops negotiation rights to Ventyx obesity, Parkinson’s candidate for $27M
News
Sep 23, 2024
SeekingAlpha - Ventyx stock climbs 8% on $27M Sanofi investment
News
Sep 23, 2024
TradingView - Sanofi CEO believes company poised for growth from new drugs
News
Sep 23, 2024
MarketScreener - Sanofi continues to study potential demerger of consumer division, says CEO